Overview
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
Status:
Completed
Completed
Trial end date:
2005-08-01
2005-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Fougera Pharmaceuticals Inc.Treatments:
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Criteria
Inclusion Criteria:- Clinical diagnosis of psoriasis or atopic dermatitis involving more than 20% of body
surface area
- Good health with the exception of psoriasis or atopic dermatitis
Exclusion Criteria:
- Any disease affecting the HPA-axis
- Subjects who are pregnant, nursing, or planning a pregnancy within the study
participation period